Eli Lilly and
LLY | NYSE
$1,417.54
+$43.84 (+3.19%)
At close: Oct 30, 2026, 4:02 PM ET
$1,411.78
-$5.76 (-0.41%)
Pre-market:
Nov 2, 2026, 4:15 AM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
Revenue | 65.18B | 45.04B | 34.12B | 28.54B | 28.32B | 24.54B |
Cost of Revenue | 11.05B | 8.42B | 7.08B | 6.63B | 7.31B | 5.48B |
Gross Profit | 54.13B | 36.63B | 27.04B | 21.91B | 21.01B | 19.06B |
Operating Income | 29.7B | 17.04B | 10.79B | 8.65B | 7.93B | 7.21B |
Interest Income | 153.3M | 175.2M | 173.6M | 62.8M | 25.4M | 33M |
Pretax Income | 25.73B | 12.68B | 6.55B | 6.81B | 6.16B | 7.23B |
Net Income | 20.64B | 10.59B | 5.24B | 6.24B | 5.58B | 6.19B |
Selling & General & Admin | 11.09B | 8.59B | 6.94B | 6.07B | 6.14B | 5.87B |
Research & Development | 13.34B | 10.99B | 9.31B | 7.19B | 6.93B | 5.98B |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 24.43B | 19.59B | 16.25B | 13.26B | 13.07B | 11.85B |
Interest Expense | 795.3M | 780.6M | 485.9M | 331.6M | 339.8M | 359.6M |
Selling & Marketing Expenses | n/a | 200K | n/a | n/a | n/a | n/a |
Cost & Expenses | 35.48B | 28B | 23.34B | 19.89B | 20.39B | 17.33B |
Income Tax Expense | 5.09B | 2.09B | 1.31B | 561.6M | 573.8M | 1.04B |
Shares Outstanding (Basic) | 898M | 900.61M | 899.38M | 950.18M | 953.65M | 956.59M |
Shares Outstanding (Diluted) | 898M | 904.06M | 903.28M | 950.18M | 953.65M | 956.59M |
EPS (Basic) | 23.07 | 11.76 | 5.83 | 6.57 | 5.85 | 6.47 |
EPS (Diluted) | 22.95 | 11.71 | 5.80 | 6.57 | 5.85 | 6.47 |
EBITDA | 31.69B | 18.81B | 8.57B | 8.66B | 8.04B | 8.91B |
EBIT | 29.7B | 17.04B | 7.04B | 7.14B | 6.5B | 7.59B |
Depreciation & Amortization | 2B | 1.77B | 1.53B | 1.52B | 1.55B | 1.32B |
Add to Watchlist
Select watchlists to add or remove LLY